Vision Monitoring Tech Company Engages Investment Banker
Friday, February 2, 2018 12:15 AM
DALLAS—Vital Art and Science, a Dallas-based technology company, has hired Telos Capital Advisors as its exclusive investment banking advisor to represent it in the sale of its myVisionTrack
technology, also known as the mVT Service. The mVT Service is an FDA-cleared 510(k) Class 1 medical device that provides people suffering from age-related macular degeneration, diabetic retinopathy, diabetic macular edema, and other ocular diseases the ability to monitor their vision at home or while they travel, in-between office appointments.
The mVT Service remotely notifies their doctor when a significant change in the patient’s vision is detected. Patients test their vision by downloading the mVT App, available in the Apple App and Google Play Store.
“Our board believes the time is right to put this technology into the marketplace. Having proven the validity, market acceptance and value of the technology, a large vision care company that already has the infrastructure in place can quickly bring the mVT Service to market and help save vision” said Mike Bartlett, president and CEO, Vital Art and Science. “In our beta launch, we found the increased frequency of at-home testing resulted in earlier detection and treatment of these vision destroying diseases.”